Risperidone
Atypical Antipsychotic – Dopamine-Serotonin Antagonist
Risperidone is an atypical (second-generation) antipsychotic medication widely used to treat schizophrenia, manic episodes in bipolar disorder, and short-term management of persistent aggression in patients with Alzheimer’s dementia and in children with conduct disorder. Risperidone works by blocking dopamine D2 and serotonin 5-HT2A receptors in the brain, which helps reduce psychotic symptoms while causing fewer movement-related side effects than older, typical antipsychotics. It is one of the most commonly prescribed antipsychotics worldwide and is included on the World Health Organization (WHO) Model List of Essential Medicines. Risperidone is available as film-coated tablets for daily oral use and as a prolonged-release depot injection (Risperdal Consta) administered every two weeks for maintenance treatment.
Quick Facts: Risperidone
Key Takeaways
- Risperidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors, making it effective for both positive symptoms (hallucinations, delusions) and negative symptoms of schizophrenia.
- It is approved for schizophrenia, acute manic episodes in bipolar disorder, short-term treatment of persistent aggression in Alzheimer’s dementia (up to 6 weeks), and conduct disorder in children aged 5 and older.
- Risperidone commonly causes elevated prolactin levels, which can lead to menstrual irregularities, sexual dysfunction, and breast-related symptoms – more so than most other atypical antipsychotics.
- Elderly patients with dementia-related psychosis have an increased risk of death and stroke when treated with antipsychotic medications, including risperidone. It should only be used for short-term management of severe aggression in this population.
- Never stop risperidone abruptly without medical guidance – your doctor will gradually reduce the dose to prevent relapse and withdrawal symptoms.
What Is Risperidone and What Is It Used For?
Risperidone belongs to the class of medications known as atypical (second-generation) antipsychotics. It is a benzisoxazole derivative that was first approved by the United States Food and Drug Administration (FDA) in 1993 and subsequently received marketing authorization from the European Medicines Agency (EMA). Since its introduction, risperidone has become one of the most widely prescribed antipsychotic medications globally and is included on the World Health Organization (WHO) Model List of Essential Medicines, underscoring its importance in treating psychiatric conditions worldwide.
Risperidone works through a combined mechanism of dopamine D2 and serotonin 5-HT2A receptor antagonism. By blocking dopamine D2 receptors in the mesolimbic pathway, risperidone effectively reduces positive psychotic symptoms such as hallucinations, delusions, and disorganized thinking. Simultaneously, its serotonin 5-HT2A receptor blockade helps modulate dopamine release in other brain pathways, reducing the risk of extrapyramidal side effects (movement disorders) compared to older, first-generation antipsychotics such as haloperidol or chlorpromazine. Risperidone also has significant affinity for alpha-1 adrenergic receptors (which can cause blood pressure changes) and histamine H1 receptors (which may contribute to sedation and weight gain).
Risperidone is approved for several clinical indications, which vary slightly between regulatory jurisdictions. The primary approved uses include:
- Schizophrenia: Treatment of schizophrenia in adults. Risperidone is effective against positive symptoms (hallucinations, delusions, thought disorder), negative symptoms (social withdrawal, emotional blunting, reduced motivation), and cognitive symptoms. It is commonly used as a first-line treatment option and can be used for both acute episodes and long-term maintenance therapy.
- Bipolar disorder – manic episodes: Treatment of moderate to severe manic episodes associated with bipolar disorder in adults. Risperidone can be used as monotherapy or in combination with mood stabilizers such as lithium or valproate. The typical treatment duration for acute mania is adjusted based on clinical response.
- Persistent aggression in Alzheimer’s dementia: Short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s disease who have not responded to non-pharmacological interventions and where there is a risk of harm to self or others. Non-drug approaches should always be tried first.
- Conduct disorder in children and adolescents: Short-term treatment (up to 6 weeks) of persistent aggression in children aged 5 years and older with intellectual disability or in adolescents with conduct disorder, when the severity of behaviors requires pharmacological treatment and non-drug interventions have been insufficient.
Risperidone is also used off-label in clinical practice for conditions such as irritability associated with autism spectrum disorder, treatment-resistant obsessive-compulsive disorder (as an augmentation strategy), and Tourette syndrome. However, these uses may not be formally approved in all countries and should only be pursued under specialist medical supervision.
The long-acting injectable form of risperidone (Risperdal Consta) provides a depot injection option for maintenance treatment of schizophrenia. Administered every two weeks as an intramuscular injection, the depot formulation ensures consistent drug levels and can be particularly beneficial for patients who have difficulty maintaining adherence to daily oral medication. Clinical studies have demonstrated that long-acting injectable risperidone significantly reduces relapse rates compared to placebo and offers predictable pharmacokinetics.
Risperidone simultaneously blocks dopamine D2 receptors and serotonin 5-HT2A receptors. In brain regions with excessive dopamine activity (the mesolimbic pathway, associated with psychosis), D2 blockade reduces hallucinations and delusions. The 5-HT2A blockade in the cortex promotes dopamine release in the prefrontal cortex, which may help improve negative symptoms and cognition while reducing the risk of movement disorders. Risperidone is metabolized by CYP2D6 into its active metabolite 9-hydroxyrisperidone (paliperidone), which has a similar pharmacological profile.
What Should You Know Before Taking Risperidone?
Before beginning treatment with risperidone, a thorough discussion with your healthcare provider about your complete medical history, current medications, and specific concerns is essential. This allows your doctor to assess whether risperidone is appropriate for you and to determine what monitoring may be necessary during treatment.
Contraindications
You should not take risperidone if you are allergic (hypersensitive) to risperidone or any of the other ingredients in the formulation. Signs of an allergic reaction may include fever, swelling of the mouth, face, lips, or tongue, difficulty breathing, itching, skin rash, or a drop in blood pressure. If you experience any signs of a serious allergic reaction, seek emergency medical attention immediately.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs, including risperidone, are at an increased risk of death and cerebrovascular adverse events (stroke and transient ischemic attack). Risperidone is only indicated for short-term treatment (up to 6 weeks) of persistent aggression in moderate to severe Alzheimer’s dementia when non-drug treatments have failed. Seek immediate medical attention if you notice sudden weakness, numbness in the face, arms, or legs, slurred speech, or sudden confusion.
Warnings and Precautions
Before starting risperidone, tell your doctor if you have any of the following conditions, as they may require special monitoring or dose adjustments:
- Heart problems: Including irregular heartbeat, tendency to low blood pressure, or if you take blood pressure medications. Risperidone can cause orthostatic hypotension (a drop in blood pressure when standing up), particularly at the start of treatment or after dose increases. Your dose may need to be adjusted.
- Risk factors for stroke: Including high blood pressure, cardiovascular disease, or problems with blood vessels in the brain. This is especially important for elderly patients.
- History of involuntary movements: Particularly tardive dyskinesia (uncontrollable movements of the tongue, mouth, and face). If these occur during treatment, your doctor may need to reduce the dose or discontinue risperidone.
- History of neuroleptic malignant syndrome (NMS): A rare but life-threatening condition characterized by high fever, muscle rigidity, sweating, and altered consciousness. If you have experienced NMS previously, inform your doctor as there is a risk of recurrence.
- Parkinson’s disease or Lewy body dementia: Risperidone can worsen motor symptoms and cause severe sensitivity reactions in patients with these conditions.
- Diabetes or risk factors for diabetes: Risperidone can affect blood glucose levels. Patients with existing diabetes should have their blood sugar monitored regularly during treatment.
- Epilepsy: Risperidone may lower the seizure threshold. If you have a history of seizures, closer monitoring may be required.
- Liver or kidney problems: If you have impaired liver or kidney function, all starting and subsequent doses should be halved and dose increases should be more gradual.
- Prolactin-dependent conditions: Risperidone commonly increases prolactin levels. If you have an abnormally high prolactin level or a possibly prolactin-dependent tumor, inform your doctor.
- Blood clots or family history of blood clots: Antipsychotic medications have been associated with venous thromboembolism, including deep vein thrombosis and pulmonary embolism.
Risperidone can cause significant weight gain, which may adversely affect your health. Your doctor should monitor your body weight regularly during treatment. Additionally, diabetes mellitus or worsening of pre-existing diabetes has been observed in patients taking risperidone. If you have diabetes, your blood glucose levels should be checked regularly.
Pregnancy and Breastfeeding
If you are pregnant, planning to become pregnant, or breastfeeding, discuss this with your doctor before starting risperidone. The decision to use risperidone during pregnancy requires careful weighing of the benefits of treating the mother’s psychiatric condition against potential risks to the developing fetus.
Neonates exposed to antipsychotic drugs, including risperidone, during the third trimester (last three months) of pregnancy may experience withdrawal symptoms after delivery. These can include tremor, muscle stiffness and/or weakness, drowsiness, agitation, breathing difficulties, and feeding problems. If your baby develops any of these symptoms, contact your healthcare provider promptly.
Risperidone may raise prolactin levels, which can affect fertility in both men and women. In women, elevated prolactin can cause menstrual irregularities or cessation of periods. In men, it can lead to breast enlargement and sexual dysfunction. If you are planning to conceive, discuss the potential impact on fertility with your doctor.
Driving and Operating Machinery
Dizziness, fatigue, and visual disturbances may occur during treatment with risperidone. Do not drive or operate machinery until you know how risperidone affects you personally. You are responsible for assessing whether you are fit to drive or perform tasks requiring alertness. One of the factors that may impair your ability is the use of medications due to their effects and/or side effects.
Risperidone film-coated tablets contain lactose. If you have been told by your doctor that you have an intolerance to some sugars, speak to your doctor before taking this medication. The tablets contain less than 1 mmol (23 mg) sodium per tablet, meaning they are essentially sodium-free.
How Does Risperidone Interact with Other Drugs?
Drug interactions with risperidone are primarily related to its metabolism through the cytochrome P450 enzyme system, particularly CYP2D6 (the main metabolic pathway) and CYP3A4 (a secondary pathway). Risperidone is converted by CYP2D6 into its active metabolite 9-hydroxyrisperidone (paliperidone), which has similar pharmacological activity. The total active moiety (risperidone plus paliperidone) determines the overall clinical effect. Understanding these interactions is essential for safe and effective treatment.
Drugs That May Decrease Risperidone’s Effect
The following drugs can reduce risperidone blood levels and may require dose adjustments:
| Interacting Drug / Class | Mechanism | Clinical Recommendation |
|---|---|---|
| Carbamazepine, phenytoin (antiepileptics) | Strong CYP3A4 induction; decreases risperidone levels substantially | May need increased risperidone dose; re-evaluate when inducer is stopped |
| Rifampicin (antibiotic for infections) | Strong CYP3A4 induction; decreases active moiety levels | May need increased risperidone dose during co-administration |
| Phenobarbital (anticonvulsant/sedative) | CYP3A4 induction; reduces risperidone plasma concentration | Monitor clinical response; adjust dose as needed |
Drugs That May Increase Risperidone’s Effect
The following medications can increase risperidone blood levels and may require dose reduction:
| Interacting Drug / Class | Mechanism | Clinical Recommendation |
|---|---|---|
| Fluoxetine, paroxetine (SSRIs) | CYP2D6 inhibition; increases risperidone plasma levels | May need reduced risperidone dose; re-evaluate when SSRI is stopped |
| Quinidine (antiarrhythmic) | Strong CYP2D6 inhibition; substantially increases risperidone levels | Reduce risperidone dose; monitor closely for side effects |
| Itraconazole, ketoconazole (antifungals) | CYP3A4 inhibition; increases active moiety concentration | May need dose reduction of risperidone |
| Verapamil (calcium channel blocker) | CYP3A4 inhibition; may increase risperidone levels | Monitor for increased side effects |
| Beta-blockers, cimetidine, ranitidine | Various CYP2D6 inhibition effects | Monitor and adjust dose if needed |
| Ritonavir (HIV medication) | Combined enzyme inhibition; increases risperidone exposure | May need significant dose reduction |
Other Important Interactions
- CNS depressants (benzodiazepines, opioids, antihistamines): Combining risperidone with other central nervous system depressants may enhance sedation, drowsiness, and dizziness. Use only under careful medical supervision.
- Antihypertensive medications: Risperidone can enhance the blood pressure-lowering effect of antihypertensive drugs, increasing the risk of orthostatic hypotension (dizziness upon standing). Monitor blood pressure closely.
- Levodopa and dopamine agonists (Parkinson’s disease drugs): Risperidone may counteract the effects of levodopa and other dopamine agonists, as it is a dopamine receptor blocker.
- Psychostimulants (methylphenidate): While risperidone and stimulants are sometimes used together (e.g., for ADHD with conduct problems), changes in either medication may require dose adjustments of the other.
- QT-prolonging medications: Use caution when combining risperidone with drugs that prolong the QT interval (some antibiotics, antiarrhythmics, antimalarials, certain antidepressants) as this may increase the risk of serious cardiac arrhythmias.
- Diuretics (furosemide, chlorothiazide): In elderly patients with dementia, the combination of risperidone with furosemide has been associated with increased mortality. If such combination is necessary, close monitoring and careful assessment of risks and benefits are required.
- Alcohol: Alcohol should be avoided during treatment with risperidone as it can increase sedation, dizziness, and impaired judgment.
In elderly patients with dementia, the use of risperidone together with furosemide (a diuretic) has been associated with an increased risk of mortality compared to treatment with risperidone or furosemide alone. Your doctor will carefully consider whether this combination is necessary and will monitor you closely if it is.
What Is the Correct Dosage of Risperidone?
Risperidone dosage varies depending on the condition being treated, the patient’s age, weight, kidney and liver function, and concomitant medications. All dose adjustments should be made by your prescribing physician. The information below provides general guidance based on current prescribing information from the European Medicines Agency (EMA) and the FDA. Risperidone can be taken with or without food. Tablets should be swallowed whole with water.
Adults – Schizophrenia
| Phase | Dose | Notes |
|---|---|---|
| Day 1 | 2 mg/day | Starting dose; can be given as one or two doses |
| Day 2 | 4 mg/day | Dose may be increased if tolerated |
| Maintenance | 4–6 mg/day | Most patients respond best in this range; once or twice daily |
| Elderly patients | Start 0.5 mg twice daily | Gradual increase to 1–2 mg twice daily |
Adults – Manic Episodes (Bipolar Disorder)
Bipolar Mania Dosing
The starting dose is usually 2 mg once daily. Your doctor may gradually adjust the dose depending on your response. Most patients feel better with daily doses between 1 and 6 mg. For elderly patients, the starting dose is 0.5 mg twice daily, which may be gradually increased to 1–2 mg twice daily.
Adults – Persistent Aggression in Alzheimer’s Dementia
Alzheimer’s Dementia Aggression
Starting dose: 0.25 mg twice daily. Your doctor may gradually adjust the dose depending on response. Most patients improve with 0.5 mg twice daily. Some patients may need up to 1 mg twice daily. Treatment duration should not exceed 6 weeks. Non-pharmacological interventions must have been tried first. Regular reassessment is required.
Children and Adolescents – Conduct Disorder
Children weighing less than 50 kg
Starting dose: 0.25 mg once daily. May be increased every other day by 0.25 mg/day. Usual maintenance dose: 0.25–0.75 mg/day.
Children weighing 50 kg or more
Starting dose: 0.5 mg once daily. May be increased every other day by 0.5 mg/day. Usual maintenance dose: 0.5–1.5 mg/day.
Important: Treatment duration for conduct disorder should not exceed 6 weeks. Children under 5 years should not be treated with risperidone for conduct disorder. Children and adolescents under 18 years should not receive risperidone for schizophrenia or mania.
Patients with Kidney or Liver Problems
If you have impaired kidney or liver function, regardless of the condition being treated, all starting and subsequent doses of risperidone should be halved. Dose increases should be slower in these patients. Risperidone should be used with caution in this group, and your doctor will monitor you more closely for side effects.
Missed Dose
If you forget to take a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten one. If you miss two or more doses, contact your doctor for guidance on how to restart treatment safely.
Overdose
If you suspect an overdose of risperidone, contact your local emergency services or poison control center immediately. Take the medication packaging with you. Symptoms of overdose may include drowsiness, fatigue, abnormal body movements, difficulty standing or walking, dizziness from low blood pressure, abnormal heartbeat, and seizures.
There is no specific antidote for risperidone overdose. Treatment is supportive with close monitoring of vital signs, cardiac function, and airway management as needed. Activated charcoal may be considered if ingestion was recent and the patient can protect their airway. In clinical overdose cases, most patients have recovered with appropriate supportive care.
What Are the Side Effects of Risperidone?
Like all medications, risperidone can cause side effects, although not everyone will experience them. The risk and type of side effects depend on the dose, duration of treatment, and individual patient factors. Some side effects are more common in specific populations – for example, children and adolescents may experience drowsiness, fatigue, and increased appetite more frequently than adults.
The following side effects are organized by frequency based on clinical trial data and post-marketing surveillance reported by the European Medicines Agency and the FDA:
Contact your doctor or emergency services immediately if you experience: signs of stroke (sudden weakness, numbness, slurred speech, especially in dementia patients); uncontrollable movements of the face, tongue, or body (tardive dyskinesia); high fever with muscle rigidity and altered consciousness (neuroleptic malignant syndrome); blood clots (leg swelling, chest pain, difficulty breathing); severe allergic reactions (swelling of face, lips, tongue, difficulty breathing); or prolonged painful erection (priapism).
Very Common
May affect more than 1 in 10 people
- Difficulty falling or staying asleep (insomnia)
- Parkinsonism: slow or impaired movement, feeling of stiff or tight muscles, jerky movements, shuffling gait, tremor at rest, increased saliva production, lack of facial expression
- Drowsiness or reduced alertness
- Headache
Common
May affect up to 1 in 10 people
- Pneumonia, respiratory tract infections, bronchitis, common cold symptoms, sinusitis, urinary tract infections, ear infections, flu-like feeling
- Raised prolactin levels (may cause breast swelling in men, difficulty with erections, decreased sex drive, menstrual irregularities in women, breast discomfort, milk leakage)
- Weight gain, increased appetite, decreased appetite
- Sleep disturbances, irritability, depression, anxiety, restlessness
- Dystonia (involuntary sustained muscle contractions), dyskinesia (involuntary movements), tremor, dizziness
- Blurred vision, eye infection
- Rapid heartbeat, high blood pressure, shortness of breath
- Sore throat, cough, nosebleeds, nasal congestion
- Abdominal discomfort, nausea, vomiting, constipation, diarrhea, indigestion, dry mouth, toothache
- Skin rash, skin redness
- Muscle spasms, musculoskeletal pain, back pain, joint pain
- Urinary incontinence
- Swelling, fever, chest pain, weakness, fatigue, pain, falls
Uncommon
May affect up to 1 in 100 people
- Decreased white blood cells, decreased platelets, anemia
- Allergic reactions, diabetes or worsening diabetes, high blood sugar, increased cholesterol
- Mania, confusion, decreased sex drive, nightmares, nervousness
- Tardive dyskinesia (uncontrollable facial movements), seizures, fainting, restless need to move (akathisia), balance problems, speech difficulties, taste changes, skin numbness or tingling
- Light sensitivity, dry eyes, increased tears, ear pain, ringing in ears (tinnitus)
- Atrial fibrillation, abnormal heart conduction, prolonged QT interval, low heart rate, palpitations
- Low blood pressure, orthostatic hypotension, flushing
- Aspiration pneumonia, wheezing, voice disturbance
- Fecal incontinence, difficulty swallowing, excessive gas
- Hives, itching, hair loss, thickened skin, eczema, dry skin, acne
- Abnormal posture, joint stiffness, joint swelling, muscle weakness, neck pain
- Frequent urination, inability to urinate, painful urination
- Erectile dysfunction, ejaculation disorders, missed periods, vaginal discharge
- Breast development in men, milk leakage, sexual dysfunction
- Facial swelling, chills, increased body temperature, thirst, chest discomfort
- Increased liver enzymes
Rare
May affect up to 1 in 1,000 people
- Inappropriate secretion of antidiuretic hormone (SIADH)
- Sleepwalking, sleep-related eating disorder
- Sugar in urine, low blood sugar, high blood triglycerides
- Inability to feel emotions, inability to achieve orgasm
- Catatonia (immobility and lack of responsiveness while awake)
- Dangerously low white blood cell count (agranulocytosis)
- Glaucoma (increased eye pressure), eye movement problems
- Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery
- Dangerous water intoxication (excessive water intake)
- Irregular heartbeat, sleep apnea
- Pancreatitis, intestinal obstruction
- Swollen tongue, cracked lips, drug-related rash
- Rhabdomyolysis (breakdown of muscle fibers)
- Breast enlargement, breast engorgement
- Jaundice (yellowing of skin and eyes)
- Lowered body temperature, cold extremities
- Drug withdrawal symptoms
Very Rare / Frequency Not Known
Reported in post-marketing surveillance
- Neuroleptic malignant syndrome (NMS): life-threatening condition with fever, muscle rigidity, sweating, altered consciousness
- Severe or life-threatening skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis)
- Life-threatening complications of poorly controlled diabetes (diabetic ketoacidosis)
- Severe allergic reaction with throat swelling and breathing difficulties (angioedema)
- Absence of intestinal movements causing obstruction
- Priapism (prolonged, painful erection requiring emergency treatment)
- Venous thromboembolism (blood clots in legs or lungs)
Additional Side Effects in Children and Adolescents
Side effects in children are generally similar to those in adults. However, the following effects were reported more frequently in children and adolescents (5–17 years) compared to adults: drowsiness or reduced alertness, fatigue, headache, increased appetite, vomiting, common cold symptoms, nasal congestion, abdominal pain, dizziness, cough, fever, tremor, diarrhea, and urinary incontinence.
A small and inconclusive study has reported increased height in children taking risperidone, but whether this is a medication effect or attributable to other factors is unknown. Before starting treatment, your child may be weighed, and weight should be monitored regularly during treatment.
How Should You Store Risperidone?
Proper storage of risperidone is important to maintain the medication’s effectiveness and safety:
- Blister-packed tablets: Store at room temperature below 30°C (86°F). Keep the tablets in their original blister pack to protect from moisture until you are ready to take them.
- Tablets in HDPE bottles: No special storage conditions are required. Keep the bottle tightly closed.
- Prolonged-release depot injection (Risperdal Consta): Store in the refrigerator (2–8°C). The reconstituted suspension should be used immediately after preparation. This formulation is administered by a healthcare professional.
Always keep this medication out of the sight and reach of children. Check the expiry date on the packaging before use – the expiry date refers to the last day of the stated month. Do not dispose of medications via household waste or drain. Return unused or expired medications to a pharmacy for proper disposal to protect the environment.
What Does Risperidone Contain?
Risperidone formulations contain the active substance risperidone along with various inactive ingredients (excipients) that are necessary for manufacturing, stability, and delivery of the medication.
Film-Coated Tablets
Risperidone film-coated tablets are available in five strengths, each with a distinctive color for easy identification:
- 0.5 mg: Reddish-brown, oval, biconvex tablet with score line on one side
- 1 mg: White, oval, biconvex tablet with score line on one side
- 2 mg: Orange, oval, biconvex tablet with score line on one side
- 3 mg: Yellow, oval, biconvex tablet with score line on one side
- 4 mg: Green, oval, biconvex tablet with score line on one side
All tablets can be divided into two equal doses using the score line. The inactive ingredients in the tablet core include lactose monohydrate, cellulose powder, microcrystalline cellulose, croscarmellose sodium, anhydrous colloidal silicon dioxide, sodium lauryl sulfate, and magnesium stearate. The film coating contains hypromellose, titanium dioxide (E171), talc, and propylene glycol. Coloring agents vary by strength: iron oxides (E172) for the 0.5 mg and 2 mg tablets, quinoline yellow (E104) for the 3 mg and 4 mg tablets, and indigotine (E132) for the 4 mg tablet.
Prolonged-Release Depot Injection
The depot injection (Risperdal Consta) contains risperidone in a microsphere formulation of poly(D,L-lactide-co-glycolide) polymer, which allows for gradual, sustained release of the medication over approximately two weeks. It is supplied as a powder with a solvent for reconstitution and is available in 25 mg and 37.5 mg strengths. This formulation is administered exclusively by healthcare professionals.
Frequently Asked Questions About Risperidone
The onset of risperidone’s effects depends on the condition being treated. For acute psychotic symptoms or agitation, some improvement may be noticed within the first few days of treatment. However, the full therapeutic benefit for conditions like schizophrenia or bipolar disorder typically develops over 4 to 6 weeks of consistent daily use. For behavioral problems in Alzheimer’s dementia, effects are usually assessed after the initial 6-week treatment period. It is important to continue taking risperidone as prescribed even if you do not notice immediate improvement, as the full benefit takes time to develop.
Yes, weight gain is a common side effect of risperidone. Clinical studies and comparative meta-analyses rank risperidone as causing moderate weight gain among atypical antipsychotics – generally more than aripiprazole or ziprasidone, but less than olanzapine or clozapine. Significant weight gain can adversely affect cardiovascular health and metabolic parameters. Your doctor should monitor your weight regularly, and adopting a healthy diet and exercise routine during treatment is recommended. If weight gain becomes problematic, your doctor may consider adjusting the dose or switching to an alternative medication.
Yes, risperidone is one of the antipsychotics most associated with elevated prolactin levels (hyperprolactinemia). This occurs because risperidone strongly blocks dopamine D2 receptors in the pituitary gland, which normally inhibit prolactin release. Elevated prolactin can cause a range of symptoms including menstrual irregularities or cessation of periods in women, breast swelling and tenderness, milk discharge from the breasts (galactorrhea), sexual dysfunction, decreased libido, and erectile difficulties in men. With long-term elevation, there may be effects on bone density. If you experience these symptoms, your doctor may check your prolactin levels and consider adjusting treatment.
Alcohol should be avoided while taking risperidone. Both substances affect the central nervous system, and combining them can significantly increase drowsiness, dizziness, impaired judgment, and difficulty concentrating. Alcohol can also worsen the psychiatric condition being treated and reduce the overall effectiveness of risperidone. If you regularly consume alcohol, discuss this with your doctor before starting treatment.
The use of risperidone during pregnancy requires careful medical supervision and a thorough risk-benefit assessment. Neonates exposed to antipsychotics including risperidone during the third trimester may experience withdrawal symptoms after birth, including tremor, muscle rigidity or weakness, drowsiness, agitation, breathing difficulties, and feeding problems. These effects are usually self-limiting but may require monitoring. The decision to continue or discontinue risperidone during pregnancy must balance the risks of fetal drug exposure against the risks of untreated maternal psychiatric illness, which can also adversely affect both mother and child. Never stop risperidone abruptly without consulting your doctor.
You should never stop risperidone suddenly without your doctor’s guidance. Abrupt discontinuation can cause withdrawal symptoms such as nausea, vomiting, sweating, and insomnia. More importantly, your original psychiatric symptoms may return or worsen rapidly. If your doctor decides that treatment should be stopped, the dose will typically be reduced gradually over several days to weeks. This gradual tapering helps minimize withdrawal effects and allows monitoring for any recurrence of symptoms. Always follow your doctor’s instructions regarding any changes to your medication regimen.
References
- European Medicines Agency (EMA). Risperdal – Summary of Product Characteristics. Last updated 2025. Available at: www.ema.europa.eu/en/medicines/human/referrals/risperdal
- U.S. Food and Drug Administration (FDA). Risperdal (risperidone) Prescribing Information. Available at: www.accessdata.fda.gov
- World Health Organization (WHO). Model List of Essential Medicines, 23rd List (2023). Geneva: WHO; 2023.
- National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. Clinical guideline CG178. Updated 2024.
- Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962. doi:10.1016/S0140-6736(13)60733-3
- Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939-951. doi:10.1016/S0140-6736(19)31135-3
- De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8(2):114-126. doi:10.1038/nrendo.2011.156
- Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):CD003476. doi:10.1002/14651858.CD003476.pub2
- Pillay J, Boylan K, Carrey N, et al. First- and Second-Generation Antipsychotics in Children and Young Adults: Systematic Review Update. Comparative Effectiveness Reviews, No. 184. AHRQ; 2017.
- British National Formulary (BNF). Risperidone. NICE Evidence Services. Updated 2025. Available at: bnf.nice.org.uk/drugs/risperidone
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Psychiatry and Clinical Pharmacology with documented academic background and clinical experience.
Medical Review
iMedic Medical Review Board – Independent panel of physicians who verify medical accuracy, evidence quality, and adherence to international guidelines (WHO, EMA, FDA, NICE, BNF).
Evidence Standard
Level 1A evidence based on systematic reviews, meta-analyses, and randomized controlled trials. GRADE evidence framework applied. No commercial funding.
Accessibility
Content reviewed for WCAG 2.2 Level AAA compliance. Optimized for screen readers, keyboard navigation, and assistive technology. High contrast support enabled.
Disclaimer: This article is for educational purposes only and does not replace professional medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.